Tuesday, August 18, 2009

Business World: Novartis, Multiple Sclerosis, FTY720, & Betaseron

From The Wall Street Journal's Health Blog:

AUGUST 17, 2009, 11:12 AM ET
Novartis’s Big Plans for Multiple Sclerosis
By Jeanne Whalen


The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis drug long sold by Bayer.

Why would Novartis want to sell somebody else’s years-old drug? Largely to gain experience in the MS marketplace as Novartis plots a future launch of the MS drug FTY720.

“It’s a way to build a strong commercial organization and a strong medical organization ahead of FTY,” Novartis pharmaceuticals chief Joe Jimemez told the Health Blog recently.


Read the full blog entry


Note: Here is a reference to FTY720:

Horga A, & Montalban X. (2008). FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev Neurother., 8(5) 699-714.

Clinical Neuroinmunology Unit, Multiple Sclerosis Center of Catalonia (CEM-Cat), Vall d'Hebron University Hospital, Barcelona, Spain.

FTY720 (fingolimod) is a structural analogue of sphingosine, an endogenous lysophospholipid, which targets sphingosine-1-phosphate receptors after biotransformation to FTY720-phosphate. The immunomodulatory properties of this agent are mainly related to its ability to entrap lymphocytes in secondary lymphoid organs, reducing their availability for cell-mediated immune responses. Emerging evidence suggests that FTY720 also exerts direct actions on glial and precursor cells of the CNS which may be relevant for the process of tissue repair after injury. The therapeutic effects of the drug observed in animal models of human multiple sclerosis have provided the experimental basis for its clinical application. A recent Phase II study has demonstrated that oral FTY720 is effective in reducing disease activity in relapsing multiple sclerosis with a favorable adverse-effect profile. These results are awaiting confirmation in the three ongoing Phase III clinical trials evaluating FTY720 for relapsing-remitting multiple sclerosis.

PMID: 18457527 [PubMed - indexed for MEDLINE

1 comment:

Stuart Schlossman said...

Unique in what we do. Bridging the gap to all major MS Organizations.
Providing information and resources from our website, daily via our blog and weekly by our e-newsletter (Stu's Views and MS Related News).

Learn more of Multiple Sclerosis when registered at:
Once registered, you will receive our weekly ms related e-newsletter, keeping you informed of current MS information.
This e-Newsletter is now being received by e-recipients in (53) Countries.

Use our MS Blog: - to your advantage.

Become A Fan of "MS Views and News":

Here is a link to Join our cause for "MS Views and News" :

-- Have questions? Write to:

Please don't forget to tell others that are affected by MS, of this information. - thank you